Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic lymphocytic leukemia, according to an analysis. A recent study highlights the ...

Minimal residual disease (MRD)-guided retreatment with anti-CD20 antibodies effectively lowers MRD levels and delays clinical relapse in patients with high-risk chronic lymphocytic leukemia (CLL), ...

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately ...

Secondary immunodeficiency disease (SID) status was associated with significantly higher risk for severe bacterial infections in adult patients with chronic lymphocytic leukemia (CLL)/small ...

Ianalumab targets the B-cell activating factor receptor (BAFR) and ibrutinib belongs to a class of therapeutics called Bruton ...

Researchers sought to determine whether zanubrutinib would outperform acalabrutinib in an indirect treatment comparison in R/R CLL.

Calquence and Venclexta, with or without Gazyva, improved PFS in untreated CLL patients compared to standard chemoimmunotherapy. The AMPLIFY trial showed reduced disease progression risk with the ...

June 11, 2009 (Berlin, Germany) — The novel CD20 monoclonal antibody ofatumumab (Arzerra) has demonstrated superior response rates in 2 challenging groups of chronic lymphocytic leukemia (CLL) ...

Preliminary analyses from the EPCORE ® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or ...